Evidence map›Paper›PMID 28700660›Full record

ArticlePloS one2017

Cancer-selective, single agent chemoradiosensitising gold nanoparticles.

Sophie Grellet, Konstantina Tzelepi, Meike Roskamp, Phil Williams, Aquila Sharif, Richard Slade-Carter, Peter Goldie, Nicky Whilde, Małgorzata A Śmiałek, Nigel J Mason and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Sophie GrelletSchool of Life, Health & Chemical Sciences, The Open University, Walton Hall, Milton Keynes, United Kingdom.
Konstantina TzelepiSchool of Life, Health & Chemical Sciences, The Open University, Walton Hall, Milton Keynes, United Kingdom.
Meike RoskampMidatech Pharma, Milton Park, Abingdon, United Kingdom.
Phil WilliamsMidatech Pharma, Milton Park, Abingdon, United Kingdom.
Aquila SharifGenesisCare, Milton Keynes Medical Centre, Milton Keynes, United Kingdom.
Richard Slade-CarterGenesisCare, Milton Keynes Medical Centre, Milton Keynes, United Kingdom.
Peter GoldieRadiotherapy Department, Northampton General Hospital NHS Trust, Northampton, United Kingdom.
Nicky WhildeRadiotherapy Department, Northampton General Hospital NHS Trust, Northampton, United Kingdom.
Małgorzata A ŚmiałekDepartment of Control and Power Engineering, Faculty of Ocean Engineering and Ship Technology, Gdansk University of Technology, Gdansk, Poland.
Nigel J MasonSchool of Physical Sciences, The Open University, Walton Hall, Milton Keynes, United Kingdom.
Jon P GoldingSchool of Life, Health & Chemical Sciences, The Open University, Walton Hall, Milton Keynes, United Kingdom.ORCID http://orcid.org/0000-0002-7910-7382
The Open University · GBMidatech Pharma (United Kingdom) · GBMilton Keynes Hospital · GBNorthampton General Hospital NHS Trust · GBGdańsk University of Technology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two nanometre gold nanoparticles (AuNPs), bearing sugar moieties and/or thiol-polyethylene glycol-amine (PEG-amine), were synthesised and evaluated for their in vitro toxicity and ability to radiosensitise cells with 220 kV and 6 MV X-rays, using four cell lines representing normal and cancerous skin and breast tissues. Acute 3 h exposure of cells to AuNPs, bearing PEG-amine only or a 50:50 ratio of alpha-galactose derivative and PEG-amine resulted in selective uptake and toxicity towards cancer cells at unprecedentedly low nanomolar concentrations. Chemotoxicity was prevented by co-administration of N-acetyl cysteine antioxidant, or partially prevented by the caspase inhibitor Z-VAD-FMK. In addition to their intrinsic cancer-selective chemotoxicity, these AuNPs acted as radiosensitisers in combination with 220 kV or 6 MV X-rays. The ability of AuNPs bearing simple ligands to act as cancer-selective chemoradiosensitisers at low concentrations is a novel discovery that holds great promise in developing low-cost cancer nanotherapeutics.

Indexed as

ApoptosisCaspase InhibitorsCell LineCell Line, TumorGoldHumansMagnetic Resonance SpectroscopyMetal NanoparticlesMicroscopy, Electron, TransmissionCaspase InhibitorsGold

Identifiers

PMID28700660
PMCPMC5507319
OpenAlexW2735053682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.